Mark Ragosa, CHIEF FINANCIAL OFFICER at Kiniksa Pharmaceuticals International, plc (KNSA), sold 24,085 shares at $21.45 ($515K) on 2024-12-03, disclosed to the SEC on 2024-12-05.
Scheduled sale ($515k) by CHIEF FINANCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.45 | 8,969 | $192K | 37.3% |
| 2 | $21.45 | 8,969 | $192K | 37.3% |
| 3 | $21.25 | 5,024 | $107K | 20.7% |
| 4 | $21.25 | 1,123 | $24K | 4.6% |
| Total | $21.40 avg | 24,085 | $515K | 100% |
| Filing → |
| KNSA | SELL | 2026-01-09 | $503K | — | Filing → |
| KNSA | SELL | 2025-12-10 | $3.6M | — | Filing → |
| KNSA | SELL | 2025-11-14 | $815K | — | Filing → |